Abbott (ABT) Tops Q2 EPS by 3c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
UBS Reiterates Buy Rating on Abbott Labs (ABT)
July 19, 2024 6:17 AM EDTUBS analyst Danielle Antalffy reiterated a Buy rating and $143.00 price target on Abbott Labs (NYSE: ABT)
The analyst comments "ABT shares closed down today despite what we view as another quarter of broad-based strength that should have been rewarded by investors, but likely... More
Evercore ISI Reiterates Outperform Rating on Abbott Labs (ABT), PT $120
July 18, 2024 8:59 AM EDTEvercore ISI analyst Vijay Kumar reiterated an Outperform rating and $120.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "ABT reported base organic revenue growth rate of ~9.3% excl. COVID, with overall revenues coming inline with ST. Fx came in ~50 bps worse than Guide, ex which total revs would have Beat slightly. This was a clean print and there were no China VBP call outs, distributor stocking dynamics or China anti-corruption impact in the Q (notable given JNJ called these out yesterday). The organic revenue growth... More
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT), PT $130
July 18, 2024 8:53 AM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $130.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Second-quarter revenue and EPS of $10.38B and $1.14 beat the Street's $10.37B and $1.11 forecasts. Organic sales growth for the base business, excluding Covid test sales,... More
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
July 18, 2024 8:50 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $115.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Delivering the sixth quarter in a row of double-digit Medical Device division (43% of 2Q sales) growth, Abbotts 2Q solid performance met expectations. As a whole, we view the companys Medical Device growth and 2H24 positive momentum commentary as a... More
Citi Reiterates Buy Rating on Abbott Labs (ABT)
July 18, 2024 8:49 AM EDTCiti analyst Joanna Wuensch reiterated a Buy rating and $119.00 price target on Abbott Labs (NYSE: ABT).
The analyst comments "Abbott delivered 2Q24 revenue of $10.38B (up 4.0% reported; up 9.3% organic ex-Covid-19), roughly in-line with consensuss $10.37B, including: Nutrition of $2.15B (up 7.5%, versus $2.16B); Diagnostics of $2.20B... More
